What PolyPid's Bold Moves in Europe Could Mea...
WSW, NY, October 9th, 2026, FinanceWire
Two announcements on the same day put a validated European application and full European commercial rights in PolyPid's hands, and may point to value well beyond the U.S. deal the market already knows about.
On October 1, PolyPid (NASDAQ: PYPD) announced two moves in Europe on the same morning. The European Medicines Agency validated the company's Marketing Authorization Application for D-PLEX₁₀₀, and PolyPid regained full European commercialization rights to the product from ADVANZ PHARMA. D-PLEX₁₀₀ is applied directly into the surgical wound before closure and releases the antibiotic doxycycline locally for about 30 days. That matches the 30-day window the CDC uses to define surgical site infections after colon surgery, and runs long after standard IV antibiotics have cleared the body.
The two moves read best together. PolyPid's lead product is now under regulatory review on both sides of the Atlantic, backed by positive Phase 3 data, an FDA Priority Review and a funded U.S. partner, and the company once again controls a major market it can partner on its own terms. The original European license was signed in 2022, before PolyPid's pivotal data existed, and its terms reflected that uncertainty, with most of the value deferred to milestones. D-PLEX₁₀₀ now potentially returns to the European partnering table with a far more advanced asset, with its Phase 3 readout behind it, and the opportunity may extend well beyond what the prior European licensing agreement was pricing into it.
Europe Is Back, on Far Stronger Footing
PolyPid submitted the MAA on September 14 under the EMA's Centralized Procedure. Validation confirms the application is complete and starts formal review, and an approval would bring a single marketing authorization valid across every European Union Member State. On the same day, PolyPid announced that it had regained exclusive European commercialization rights to D-PLEX₁₀₀ from ADVANZ Pharma. CEO Dikla Czaczkes Akselbrad tied the decision directly to the program's progress: "Since entering into the original agreement in 2022, several transformative milestones have been achieved... We believe that this makes D-PLEX₁₀₀ a highly attractive opportunity for multinational pharmaceutical companies looking to enhance their product portfolio in the surgical site infection space in Europe and other large markets."
That progress is easy to measure. When the European license was signed, PolyPid's pivotal readout was still ahead of it and the deal carried a €2.5 million (approximately $2.6 million) upfront payment, a small slice of a package PolyPid valued at potentially more than $110 million. Since then, SHIELD II, a 798-patient Phase 3 trial in abdominal colorectal surgery, has met its primary endpoint and all key secondary endpoints, including a 60% relative risk reduction in surgical site infections (SSIs) versus standard of care (p=0.0013). The FDA accepted the New Drug Application with Priority Review and set a November 28, 2026 PDUFA goal date. In July, Azurity Pharmaceuticals licensed U.S. and Canadian rights in a deal that has already delivered $30 million to PolyPid. The agreement also carries eligibility for approximately $290 million in additional milestones, tiered royalties from the mid-teens to the mid-twenties, and a transfer price on product PolyPid manufactures. That $30 million alone is more than ten times the prior European deals upfront, and the deal's mix of near-term cash, milestones, royalties and a transfer price gives PolyPid a recent template as it looks for a European partner.
Comparable deals set a useful benchmark. When ADVANZ licensed Dimerix's Phase 3 kidney candidate for Europe and other territories in October 2023, while that trial was still running, it paid €6.5 million upfront, more than double what D-PLEX₁₀₀ commanded at a similar pre-readout stage, with up to €132 million in milestones. The European partnership has rarely come up in PolyPid's communications in recent years and may never have figured meaningfully in how the market values the company. It now becomes a live opportunity in a market with real need: ECDC surveillance put the SSI rate after open colon surgery in Europe at 10.2% in 2023, and the EU-27 recorded roughly 356,000 new colorectal cancer cases in 2022.
A Product, and a Platform, With Room to Grow
Europe is one of several potential levers. Under the Azurity agreement, the partners plan to pursue label expansion beyond abdominal surgery with Azurity funding the work, and management has named C-section and joint replacement as candidates. In the EU alone, about 1.10 million caesarean sections and 1.06 million hip replacements were performed in 2023, according to Eurostat.
PolyPid also retains rights across Asia and Latin America, where the burden may be even greater. China recorded about 517,000 new colorectal cancer cases in 2022, the most of any country, and a 2024 meta-analysis of Chinese studies placed the colorectal SSI rate at 12.5%. In India, a study by the Indian Council of Medical Research estimated roughly 1.5 million SSIs a year.
Underneath all of it sits Kynatrix, the controlled-release platform PolyPid owns outright. On its August earnings call, management said it is "exploring exciting areas that go beyond prevention and into treatment applications," alongside a long-acting metabolic program. Seen that way, D-PLEX₁₀₀ may be the platform's first proof point, with more to follow.
The Setup From Here
The coming months bring the FDA's November 28 PDUFA target action date, an anticipated early 2027 U.S. launch with Azurity, CHMP review in Europe, and a European partnering process that now begins from a validated filing, positive Phase 3 data and a manufacturing facility that has already passed Israeli Ministry of Health GMP inspections European regulators rely on for EU GMP certification. PolyPid has also said it believes its current cash, together with expected Azurity proceeds and future potential proceeds, will fund operations into 2028 and through several significant upcoming potential milestones. At the same time, drug development and regulatory review carry real risk, and no outcome is guaranteed.
Meanwhile, PolyPid remains largely under the radar, with a market capitalization of approximately $100 million. Against that sits a single U.S. agreement whose upfront and milestone payments alone reach up to approximately $320 million ($30 million of which has already been received). On top of those come tiered royalties from the mid-teens to the mid-twenties, which could add meaningfully if D-PLEX₁₀₀ is approved and gains traction, plus a pre-agreed transfer price on product PolyPid supplies, which further sweetens the deal. All of that comes from one agreement, for one product, in two countries, built on one platform. With Europe now back on the table and much of the world still unpartnered, if PolyPid plays its cards right, the D-PLEX₁₀₀ story may only be getting started.
Recent News Highlights from PolyPid (NASDAQ: PYPD)
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
PolyPid Announces Participation in Upcoming Fall Investor Conferences
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
Read this Next >>
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from PolyPid Ltd. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer. Images may be computer generated and are for entertainment and visualization purposes only, and may not be an accurate or exact depiction of the technology.
Contact
Wall Street Wirecoverage@wallstwire.ai